Clearline Capital’s Antares Pharma, Inc. ATRS Stock Holding History

Clearline Capital’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-240,685	Closed	-$987K	–	169
2022 Q1	$987K	Buy	240,685 +34,600	+17%	+$126K	0.11%	91
2021 Q4	$736K	Buy	206,085 +107,721	+110%	+$377K	0.08%	100
2021 Q3	$358K	Buy	98,364 +16,600	+20%	+$67.1K	0.03%	130
2021 Q2	$356K	Buy	+81,764	New	+$333K	0.05%	128

Other funds holding ATRS

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Clearline Capital's ATRS Position: Q2 2022 in Review

Clearline Capital sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 240,685 shares — an estimated $987K sold.

Clearline Capital first reported a position in ATRS in Q2 2021 and held it in 4 quarters. The position peaked at $987K in Q1 2022. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.

Clearline Capital reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
Clearline Capital sold 240,685 Antares Pharma, Inc. shares in Q2 2022, an estimated $987K.
Clearline Capital first reported a position in Antares Pharma, Inc. in Q2 2021 and held it in 4 quarters.
Clearline Capital's Antares Pharma, Inc. position peaked at $987K in Q1 2022.
1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.

Based on Clearline Capital's 13F filing for Q2 2022, filed 15 Aug 2022.